Literature DB >> 18953272

Integrase inhibitors: a clinical review of raltegravir and elvitegravir.

Philip Grant1, Andrew Zolopa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18953272

Source DB:  PubMed          Journal:  J HIV Ther        ISSN: 1462-0308


× No keyword cloud information.
  6 in total

1.  Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration.

Authors:  Supachai Sakkhachornphop; Carlos F Barbas; Rassamee Keawvichit; Kanlaya Wongworapat; Chatchai Tayapiwatana
Journal:  Hum Gene Ther       Date:  2012-05-08       Impact factor: 5.695

Review 2.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

3.  Designed zinc finger protein interacting with the HIV-1 integrase recognition sequence at 2-LTR-circle junctions.

Authors:  Supachai Sakkhachornphop; Supat Jiranusornkul; Kanchanok Kodchakorn; Sawitree Nangola; Thira Sirisanthana; Chatchai Tayapiwatana
Journal:  Protein Sci       Date:  2009-11       Impact factor: 6.725

4.  Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.

Authors:  S Saravanan; M Vidya; P Balakrishnan; P Balakrishanan; N Kumarasamy; Sunil S Solomon; S Solomon; Rami Kantor; David Katzenstein; Bharat Ramratnam; Kenneth H Mayer
Journal:  J Virol Methods       Date:  2009-04-02       Impact factor: 2.014

Review 5.  Clinical management of HIV drug resistance.

Authors:  Karoll J Cortez; Frank Maldarelli
Journal:  Viruses       Date:  2011-04-14       Impact factor: 5.048

6.  HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.

Authors:  Miłosz Parczewski; Dorota Bander; Anna Urbańska; Anna Boroń-Kaczmarska
Journal:  BMC Infect Dis       Date:  2012-12-21       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.